ClinicalTrials.gg
CompletedNCT00839800SAKURAUpdated Nov 30, 2012Results posted

Study to Investigate the Efficacy of Symbicort® SMART.

A Phase 3 interventional study of Symbicort Turbuhaler and Terbutaline Turbuhaler in Asthma, sponsored by AstraZeneca. Completed at 109 sites in 12 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2012-11-30.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,091
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.

Enrollment
13th of 248
2,091 · median 175
Started
2009
with 15 others
Phase 3
121 of 359
6 open now
Registered
120th of 359
by date

Among the 359 studies in Asthma by AstraZeneca, this one is the 13th largest by enrollment of the 248 interventional ones that give a count, is one of 16 that started in 2009, is one of 121 in phase 3, and was the 120th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 359 studies in Asthma by AstraZeneca, or all of them as a file.
02

Study summary

The primary objective of this study is to compare the efficacy of Symbicort SMART (Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus as needed) with Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus terbutaline Turbuhaler 0.4 mg as needed, as asthma therapy

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Symbicort Turbuhaler
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of asthma according to the Global Initiative for Asthma guidelines (GINA) 2007 with a documented history of at least 6 months duration.
  • Reversible airway obstruction, defined as an increase in ≥12% relative to baseline for all patients 15-30 minutes after inhalation of in total 2 x 0.4 mg terbutaline Turbuhaler
  • Prescribed use of inhaled steroid (GCS) (any brand) for at least 12 weeks.

Exclusion criteria

Exclusion Criteria:

  • Respiratory infection affecting the asthma, as judged by the investigator, within 4 weeks.
  • Intake of oral, rectal or parenteral GCS within 4 weeks and/or depot parenteral GCS within 12 weeks.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,091 participants (actual)

Study arms

  • Experimental
    1

    Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + Symbicort Turbuhaler 160/4.5 µg as needed

    Drug: Symbicort Turbuhaler

  • Active comparator
    2

    Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + terbutaline Turbuhaler 0.4 mg as needed

    Drug: Symbicort Turbuhaler · Drug: Terbutaline Turbuhaler

Interventions

06

What researchers measure

Primary outcomes

  1. The Percentage of Participants Who Had Experienced Asthma Exacerbation(s) at the End of the Study

    Asthma exacerbation was defined as deterioration in asthma leading to oral glucocorticosteroid \[GCS\] treatment, hospitalization, or emergency room \[ER\] treatment.

    Time frame: week 52

Secondary outcomes

  1. Number of Asthma Exacerbations

    Asthma exacerbation was defined as deterioration in asthma leading to oral GCS treatment, hospitalization, or ER treatment. Number of asthma exacerbations during 52 weeks treatment was presented here.

    Time frame: up to 52 weeks

  2. Morning Peak Expiratory Flow (PEF)

    The mean value from a 52-week treatment period.

    Time frame: 52-week treatment period

  3. Evening PEF

    The mean value from a 52-week treatment period.

    Time frame: 2-week run-in period (14 - 18 days before randomization - week 0) and a 52-week treatment period

  4. Forced Expiratory Volume in One Second (FEV1)

    The mean value for Weeks 4, 12, 24, 36 and 52 was analysed.

    Time frame: 4, 12, 24, 36 and 52 weeks after randomization

  5. Use of As-needed Medication

    The mean value of total daily number of inhalations from the treatment period for use of as-needed medication (daytime, night-time).

    Time frame: 52-week treatment period

  6. Asthma Symptom Score

    The mean value from the treatment period for Total Asthma Symptom Score (total score: 0 is best - no asthma symptoms; 6 is worst).

    Time frame: 52-week treatment period

  7. Nights With Awakening(s) Due to Asthma Symptoms

    The mean value from the treatment period was presented here.

    Time frame: 52-week treatment period

  8. The Percentage of Participants Who Had Experienced First Mild Asthma Exacerbations

    Mild asthma exacerbation was defined as morning PEF ≥20% below baseline, daily as-needed medication use ≥2 inhalations above baseline, or a night with awakening due to asthma symptoms. The percentage of participants who had experienced mild asthma exacerbation(s) at the end of the study was presented here.

    Time frame: up to 52 weeks

  9. Symptom-free Days (no Symptoms and no Awakenings)

    A symptom-free day was defined as a day without daytime or night-time symptoms and without night-time awakenings due to asthma symptoms. The mean value was presented here.

    Time frame: 52-week treatment period

  10. Percentage of As-needed-free Days

    An as-needed-free day is defined as a night and day with no use of as-needed medication. The mean value from the treatment period was presented here.

    Time frame: 52-week treatment period

  11. Percentage of Asthma-control Days (no Asthma Symptoms, no Awakenings, and no As-needed Use)

    An asthma-control day was defined as a a night and day with no asthma symptoms, no awakenings due to asthma symptoms, and no as-needed medication use. The mean value from the treatment period was presented here.

    Time frame: 52-week treatment period

  12. Asthma Control Questionnaire (ACQ)

    The ACQ developed by Juniper and colleagues (Juniper et al 1999) was used without the FEV1 and Beta 2-agonist questions. The Asthma Control Questionnaire has 5 questions that are assessed on a 7-point scale from 0 to 6 where 0 represents good control and 6 represents poor control. The overall score is the mean of the five responses. At least 4 out of the 5 questions must have been answered to provide a value. The mean of the overall score for Weeks 4 to 52 was presented here.

    Time frame: 4, 12, 24, 36 and 52 weeks after randomization

07

Results

Posted Nov 30, 2012

Participant flow

The first participant entered the study on 16 February 2009, and the last participant completed the study on 23 February 2011. A total of 3209 participants were enrolled at 148 centres in 13 countries in Asia, America and Europe, and 2091 participants who fulfilled the randomisation criteria were randomised.

Participant flow — Overall Study
MilestoneSymbicort SMARTSymbicort+Terbutaline As Needed
Started10491042
Completed956932
Not completed93110
Withdrew: Adverse event812
Withdrew: Lost to follow-up3126
Withdrew: Withdrawal by subject2834
Withdrew: Incorrect enrolment33
Withdrew: Study-specific discontinuation criteria613
Withdrew: Safety reasons21
Withdrew: Other814
Withdrew: Severe non-compliance to protocol77

Outcome measures

PrimaryThe Percentage of Participants Who Had Experienced Asthma Exacerbation(s) at the End of the Study

Asthma exacerbation was defined as deterioration in asthma leading to oral glucocorticosteroid \[GCS\] treatment, hospitalization, or emergency room \[ER\] treatment.

Time frame:
week 52
Reported as:
Number · percentage of participants
The Percentage of Participants Who Had Experienced Asthma Exacerbation(s) at the End of the Study
percentage of participantsSymbicort SMARTSymbicort+Terbutaline As Needed
The Percentage of Participants Who Had Experienced Asthma Exacerbation(s) at the End of the Study1622
SecondaryNumber of Asthma Exacerbations

Asthma exacerbation was defined as deterioration in asthma leading to oral GCS treatment, hospitalization, or ER treatment. Number of asthma exacerbations during 52 weeks treatment was presented here.

Time frame:
up to 52 weeks
Reported as:
Number · Asthma exacerbations
Number of Asthma Exacerbations
Asthma exacerbationsSymbicort SMARTSymbicort+Terbutaline As Needed
Number of Asthma Exacerbations259363
SecondaryMorning Peak Expiratory Flow (PEF)

The mean value from a 52-week treatment period.

Time frame:
52-week treatment period
Reported as:
Mean · Liter/minute (L/min)
Morning Peak Expiratory Flow (PEF)
Liter/minute (L/min)Symbicort SMARTSymbicort+Terbutaline As Needed
Morning Peak Expiratory Flow (PEF)331.8 ± 102.2324.7 ± 101.9
SecondaryEvening PEF

The mean value from a 52-week treatment period.

Time frame:
2-week run-in period (14 - 18 days before randomization - week 0) and a 52-week treatment period
Reported as:
Mean · L/min
Evening PEF
L/minSymbicort SMARTSymbicort+Terbutaline As Needed
Evening PEF334.2 ± 102.6327.8 ± 103.1
SecondaryForced Expiratory Volume in One Second (FEV1)

The mean value for Weeks 4, 12, 24, 36 and 52 was analysed.

Time frame:
4, 12, 24, 36 and 52 weeks after randomization
Reported as:
Geometric mean · Liter (L)
Forced Expiratory Volume in One Second (FEV1)
Liter (L)Symbicort SMARTSymbicort+Terbutaline As Needed
Forced Expiratory Volume in One Second (FEV1)2.258 ± 0.762.222 ± 0.77
SecondaryUse of As-needed Medication

The mean value of total daily number of inhalations from the treatment period for use of as-needed medication (daytime, night-time).

Time frame:
52-week treatment period
Reported as:
Mean · inhalations/day
Use of As-needed Medication
inhalations/daySymbicort SMARTSymbicort+Terbutaline As Needed
Use of As-needed Medication1.21 ± 1.391.46 ± 1.60
SecondaryAsthma Symptom Score

The mean value from the treatment period for Total Asthma Symptom Score (total score: 0 is best - no asthma symptoms; 6 is worst).

Time frame:
52-week treatment period
Reported as:
Mean · units on a scale
Asthma Symptom Score
units on a scaleSymbicort SMARTSymbicort+Terbutaline As Needed
Asthma Symptom Score1.12 ± 1.041.22 ± 1.02
SecondaryNights With Awakening(s) Due to Asthma Symptoms

The mean value from the treatment period was presented here.

Time frame:
52-week treatment period
Reported as:
Mean · Nights With Awakening(s)
Nights With Awakening(s) Due to Asthma Symptoms
Nights With Awakening(s)Symbicort SMARTSymbicort+Terbutaline As Needed
Nights With Awakening(s) Due to Asthma Symptoms15.7 ± 27.117.5 ± 27.2
SecondaryThe Percentage of Participants Who Had Experienced First Mild Asthma Exacerbations

Mild asthma exacerbation was defined as morning PEF ≥20% below baseline, daily as-needed medication use ≥2 inhalations above baseline, or a night with awakening due to asthma symptoms. The percentage of participants who had experienced mild asthma exacerbation(s) at the end of the study was presented here.

Time frame:
up to 52 weeks
Reported as:
Number · percentage of participants
The Percentage of Participants Who Had Experienced First Mild Asthma Exacerbations
percentage of participantsSymbicort SMARTSymbicort+Terbutaline As Needed
The Percentage of Participants Who Had Experienced First Mild Asthma Exacerbations7180
SecondarySymptom-free Days (no Symptoms and no Awakenings)

A symptom-free day was defined as a day without daytime or night-time symptoms and without night-time awakenings due to asthma symptoms. The mean value was presented here.

Time frame:
52-week treatment period
Reported as:
Mean · symptom-free days
Symptom-free Days (no Symptoms and no Awakenings)
symptom-free daysSymbicort SMARTSymbicort+Terbutaline As Needed
Symptom-free Days (no Symptoms and no Awakenings)45.5 ± 37.841.6 ± 37.2
SecondaryPercentage of As-needed-free Days

An as-needed-free day is defined as a night and day with no use of as-needed medication. The mean value from the treatment period was presented here.

Time frame:
52-week treatment period
Reported as:
Mean · percentage of as-needed-free days
Percentage of As-needed-free Days
percentage of as-needed-free daysSymbicort SMARTSymbicort+Terbutaline As Needed
Percentage of As-needed-free Days51.4 ± 36.747.2 ± 36.7
SecondaryPercentage of Asthma-control Days (no Asthma Symptoms, no Awakenings, and no As-needed Use)

An asthma-control day was defined as a a night and day with no asthma symptoms, no awakenings due to asthma symptoms, and no as-needed medication use. The mean value from the treatment period was presented here.

Time frame:
52-week treatment period
Reported as:
Mean · percentage of asthma-control days
Percentage of Asthma-control Days (no Asthma Symptoms, no Awakenings, and no As-needed Use)
percentage of asthma-control daysSymbicort SMARTSymbicort+Terbutaline As Needed
Percentage of Asthma-control Days (no Asthma Symptoms, no Awakenings, and no As-needed Use)41.7 ± 37.337.9 ± 36.6
SecondaryAsthma Control Questionnaire (ACQ)

The ACQ developed by Juniper and colleagues (Juniper et al 1999) was used without the FEV1 and Beta 2-agonist questions. The Asthma Control Questionnaire has 5 questions that are assessed on a 7-point scale from 0 to 6 where 0 represents good control and 6 represents poor control. The overall score is the mean of the five responses. At least 4 out of the 5 questions must have been answered to provide a value. The mean of the overall score for Weeks 4 to 52 was presented here.

Time frame:
4, 12, 24, 36 and 52 weeks after randomization
Reported as:
Mean · units on a scale
Asthma Control Questionnaire (ACQ)
units on a scaleSymbicort SMARTSymbicort+Terbutaline As Needed
Asthma Control Questionnaire (ACQ)1.162 ± 0.781.289 ± 0.75

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Symbicort SMART—41/1,049 (3.9%)279/1,049 (26.6%)
Symbicort+Terbutaline As Needed—74/1,042 (7.1%)293/1,042 (28.1%)
Most frequent serious events
Showing 10 of 74
Most frequent serious events
EventSymbicort SMARTSymbicort+Terbutaline As Needed
AsthmaRespiratory, thoracic and mediastinal disorders5/104931/1042
PneumoniaInfections and infestations4/10492/1042
GastroenteritisInfections and infestations1/10493/1042
Abdominal PainGastrointestinal disorders3/10490/1042
Traumatic Brain InjuryInjury, poisoning and procedural complications0/10492/1042
Type 2 Diabetes MellitusMetabolism and nutrition disorders0/10492/1042
DyspnoeaRespiratory, thoracic and mediastinal disorders1/10492/1042
TracheobronchitisInfections and infestations2/10490/1042
Upper Respiratory Tract Infection BacterialInfections and infestations2/10490/1042
Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/10490/1042
Most frequent other events
Most frequent other events
EventSymbicort SMARTSymbicort+Terbutaline As Needed
NasopharyngitisInfections and infestations137/1049133/1042
BronchitisInfections and infestations69/104977/1042
Viral Upper Respiratory Tract InfectionInfections and infestations60/104972/1042
PharyngitisInfections and infestations49/104958/1042

Baseline characteristics

Age Continuous
Age Continuous(years)Symbicort SMARTSymbicort+Terbutaline As NeededTotal
Mean45.7 (16 to 84)45.6 (16 to 85)45.7 (16 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)Symbicort SMARTSymbicort+Terbutaline As NeededTotal
Female7226921414
Male327350677
08

Study locations

109 sites
  • Research Site
    Capital Federal, Buenos Aires, Argentina
  • Research Site
    Mar Del Plata, Buenos Aires, Argentina
  • Research Site
    Monte Grande, Buenos Aires, Argentina
  • Research Site
    Quilmes, Buenos Aires, Argentina
  • Research Site
    Rosario, Santa Fe, Argentina
  • Research Site
    San Miguel de Tucuman, Tucuman, Argentina
  • Research Site
    Buenos Aires, Argentina
  • Research Site
    Ciudad de Buenos Aires, Argentina
  • Research Site
    Santa Fe, Argentina
  • Research Site
    Porto Alegre, Brasil, Brazil
  • Research Site
    Belo Horizonte, MG, Brazil
  • Research Site
    Juiz de Fora, MG, Brazil
  • Research Site
    Rio de Janeiro, RJ, Brazil
  • Research Site
    Porto Alegre, RS, Brazil
  • Research Site
    Florianopolis, Santa Catarina, Brazil
  • Research Site
    Santo Andre, SP, Brazil
  • Research Site
    Shenyang, Liaoning, China
  • Research Site
    Hangzhou, Zhejiang, China
  • Research Site
    Chongqing, China
  • Research Site
    Guang Zhou, China
  • Research Site
    Nanjing, China
  • Research Site
    Qingdao, China
  • Research Site
    Shanghai, China
  • Research Site
    Xi An, China
  • Research Site
    Tres Rios, Cartago, Costa Rica
  • Research Site
    Barrio San Bosco, San Jose, Costa Rica
  • Research Site
    Budapest, Hungary
  • Research Site
    Cegled, Hungary
  • Research Site
    Debrecen, Hungary
  • Research Site
    Deszk, Hungary
  • Research Site
    Gyula, Hungary
  • Research Site
    Nyiregyhaza, Hungary
  • Research Site
    Szazhalombatta, Hungary
  • Research Site
    Bangalore, Karnataka, India
  • Research Site
    Mangalore, Karnataka, India
  • Research Site
    Mysore, Karnataka, India
  • Research Site
    Trivandrum, Kerala, India
  • Research Site
    Mumbai, Maharashtra, India
  • Research Site
    Nagpur, Maharashtra, India
  • Research Site
    Pune, Maharashtra, India
  • Research Site
    Jaipur, Rajasthan, India
  • Research Site
    Coimabatore, Tamilnadu, India
  • Research Site
    Noida, India
  • Research Site
    Komaki, Aichi, Japan
  • Research Site
    Seto, Aichi, Japan
  • Research Site
    Asahi, Chiba, Japan
  • Research Site
    Matsuyama, Ehime, Japan
  • Research Site
    Kitakyusyu, Fukuoka, Japan
  • Research Site
    Yanagawa, Fukuoka, Japan
  • Research Site
    Isesaki, Gunma, Japan
  • Research Site
    ORA, Gunma, Japan
  • Research Site
    Fukuyama, Hiroshima, Japan
  • Research Site
    Hiroshima-shi, Hiroshima, Japan
  • Research Site
    Asahikawa, Hokkaido, Japan
  • Research Site
    Chitose, Hokkaido, Japan
  • Research Site
    Sapporo, Hokkaido, Japan
  • Research Site
    Tomakomai, Hokkaido, Japan
  • Research Site
    AKO, Hyogo, Japan
  • Research Site
    Himeji, Hyogo, Japan
  • Research Site
    Kobe-city, Hyogo, Japan
  • Research Site
    Hitachi, Ibaraki, Japan
  • Research Site
    Naka-gun, Ibaraki, Japan
  • Research Site
    Morioka, Iwate, Japan
  • Research Site
    Sakaide, Kagawa, Japan
  • Research Site
    Kawasaki-shi, Kanagawa, Japan
  • Research Site
    Kawasaki, Kanagawa, Japan
  • Research Site
    Yokohama, Kanagawa, Japan
  • Research Site
    Sendai, Miyagi, Japan
  • Research Site
    Nagaoka, Niigata, Japan
  • Research Site
    Beppu, Oita, Japan
  • Research Site
    Kurashiki, Okayama, Japan
  • Research Site
    Sakai, Osaka, Japan
  • Research Site
    Matsue, Shimane, Japan
  • Research Site
    Utsunomiya, Tochigi, Japan
  • Research Site
    Chuo, Tokyo, Japan
  • Research Site
    Itabashi, Tokyo, Japan
  • Research Site
    Kodaira, Tokyo, Japan
  • Research Site
    Kokubunji, Tokyo, Japan
  • Research Site
    Machida, Tokyo, Japan
  • Research Site
    Nakano-ku, Tokyo, Japan
  • Research Site
    Toshima-ku, Tokyo, Japan
  • Research Site
    Fukuoka, Japan
  • Research Site
    Kagoshima, Japan
  • Research Site
    Kochi, Japan
  • Research Site
    Kyoto, Japan
  • Research Site
    Niigata, Japan
  • Research Site
    Oita, Japan
  • Research Site
    Okayama, Japan
  • Research Site
    Bucheon, Korea, Republic of
  • Research Site
    Cheongju, Korea, Republic of
  • Research Site
    Seoul, Korea, Republic of
  • Research Site
    Suwon, Korea, Republic of
  • Research Site
    Kubang Kerian, Kelantan, Malaysia
  • Research Site
    Kuantan, Pahang, Malaysia
  • Research Site
    Batu Caves, Selangor, Malaysia
  • Research Site
    Kuala Lumpur, Malaysia
  • Research Site
    Penang, Malaysia
  • Research Site
    Surco, Lima, Peru
  • Research Site
    Lima, Peru
  • Research Site
    Lipa City, Batangas, Philippines

Showing the first 100 of 109 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Zhang O, Minku LL, Gonem S. Detecting asthma exacerbations using daily home monitoring and machine learning. J Asthma. 2021 Nov;58(11):1518-1527. doi: 10.1080/02770903.2020.1802746. Epub 2020 Aug 14. PubMed 32718193 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2012, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2009
First posted
Feb 10, 2009
Start
Feb 2009
Primary completionActual
Feb 2011
CompletionActual
Feb 2011
Results first posted
Nov 30, 2012
Last update
Nov 30, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00839800
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 10, 2009
Start date
Feb 2009
Primary completion
Feb 2011
Completion
Feb 2011
Results posted
Nov 30, 2012
Last update
Nov 30, 2012

Study contacts

Tomas Andersson, MD
study director · AstraZeneca R&D Lund
Tito Atienza, M.D.
principal investigator · Mary Mediatrix Medical Center, Lipa City, Philippines

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol

Start the discussion